Symbols

ANIP

ANI Pharmaceuticals·NASDAQ

--(--)

ANIP fundamentals

ANIP Q4 2025 Earnings

ANI Pharmaceuticals (ANIP) released its earnings on Feb 27, 2026: revenue was 247.06M (YoY +29.64%), beat estimates; EPS was 2.33 (YoY +42.94%), beat estimates.

Revenue / YoY

247.06M

+29.64%

EPS / YoY

2.33

+42.94%

Report date

Feb 27, 2026

ANIP Earnings Call Summary for Q4,2025

Revenue Growth: 2025 total revenue up 44% to $883.4M; 2026 guided for $1.055B-$1.115B (19-26% growth)
Cortrophin Expansion: 2026 sales force expansion targeting 55-65% growth; 2025 gout utilization at 15% of volumes
Generics Cash Flow: 2025 generics revenue up 28% to $384.1M; 10-15 launches/year
Financial Targets: 2026 EBITDA $275M-$290M (20-26% growth); rare disease to account for 60% of revenue
Risk Points: Royalty rate step-up (28% blended rate) impacting margins; Q1 2026 Cortrophin seasonality

Earnings

EPS

Revenue

Revenue & Expenses

ANIP has released its 2025 Q4 earnings report, with revenue of 247.06M, reflecting a YoY change of 29.64%, and net profit of 27.49M, showing a YoY change of 367.52%. The Sankey diagram below clearly presents ANIP's revenue sources and cost distribution.

Key Indicators

ANI Pharmaceuticals (ANIP) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

ANI Pharmaceuticals (ANIP)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

ANI Pharmaceuticals (ANIP)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

ANI Pharmaceuticals (ANIP)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown